AstraZeneca plc (AZN)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
- Symbol
- AZN
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $126.58B
- 52 week range
- 145.8 - 212.71
Valuation
- Share price
- $163.33 (close of 2026-09-23)
- P/E (TTM)
- 19.35x
- Price to book
- 2.82x
- Price to free cash flow
- 6.62x
- Enterprise value
- $152.36B
- Book value per share
- $57.82
Price performance
| Period | Change |
|---|
| 1 day | -2.84% |
| 5 days | +0.91% |
| 1 month | -1.60% |
| 3 months | -9.77% |
| 6 months | -11.27% |
| Year to date | -11.17% |
| 1 year | +7.50% |
| 3 years | +20.39% |
| 5 years | +37.30% |
| 10 years | +140.40% |
| All time | +1520.34% |
Profitability and growth
- Return on equity
- 20.99%
- Return on invested capital
- 16.04%
- Return on assets
- 8.96%
- Return on capital employed
- 16.47%
- Gross margin
- 81.90%
- Net margin
- 17.41%
- EBITDA margin
- 23.40%
- Revenue growth
- 8.63%
- Net income growth
- 45.34%
- Free cash flow growth
- 18.40%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 15.11%
- Current ratio
- 0.86x
- Net debt to EBITDA
- 2.41x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $58.74B
- Cost of revenue
- $10.63B
- Gross profit
- $48.11B
- EBITDA
- $13.74B
- Net income
- $10.22B
- Earnings per share
- $6.60
- Research and development
- $14.23B
- Interest expense
- $1.69B
- Shares outstanding
- 1.55B
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $58.74B | $48.11B | $10.22B | $6.60 |
| 2024-12-31 | $54.07B | $43.87B | $7.04B | $4.54 |
| 2023-12-31 | $45.81B | $37.54B | $5.96B | $3.84 |
| 2022-12-31 | $44.35B | $31.96B | $3.29B | $4.24 |
| 2021-12-31 | $37.42B | $24.98B | $112.00M | $0.16 |
| 2020-12-31 | $26.62B | $21.32B | $3.20B | $4.88 |
| 2019-12-31 | $24.38B | $19.46B | $1.33B | $2.06 |
| 2018-12-31 | $22.09B | $17.15B | $2.15B | $3.40 |
| 2017-12-31 | $22.46B | $18.15B | $3.00B | $4.74 |
| 2016-12-31 | $23.00B | $18.88B | $3.50B | $5.54 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 81.90% | 17.41% | 20.99% | 16.04% |
| 2024-12-31 | 81.12% | 13.01% | 17.21% | 12.75% |
| 2023-12-31 | 81.95% | 13.00% | 15.20% | 11.75% |
| 2022-12-31 | 72.06% | 7.41% | 8.87% | 6.26% |
| 2021-12-31 | 66.76% | 0.30% | 0.29% | 1.70% |
| 2020-12-31 | 80.09% | 12.01% | 20.44% | 16.89% |
| 2019-12-31 | 79.82% | 5.47% | 9.15% | 10.16% |
| 2018-12-31 | 77.66% | 9.76% | 15.34% | 12.75% |
| 2017-12-31 | 80.78% | 13.36% | 18.03% | 12.73% |
| 2016-12-31 | 82.06% | 15.21% | 20.99% | 18.19% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $5.71B | $24.71B |
| 2024-12-31 | $5.49B | $26.51B |
| 2023-12-31 | $5.84B | $22.36B |
| 2022-12-31 | $6.17B | $22.96B |
| 2021-12-31 | $6.33B | $28.13B |
| 2020-12-31 | $7.83B | $17.50B |
| 2019-12-31 | $5.37B | $15.73B |
| 2018-12-31 | $4.83B | $17.36B |
| 2017-12-31 | $3.32B | $15.56B |
| 2016-12-31 | $5.02B | $14.50B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $11.77B | $719.00M |
| 2024-12-31 | $9.94B | $660.00M |
| 2023-12-31 | $8.98B | $579.00M |
| 2022-12-31 | $8.72B | $619.00M |
| 2021-12-31 | $4.87B | $615.00M |
| 2020-12-31 | $3.84B | $277.00M |
| 2019-12-31 | $1.99B | $259.00M |
| 2018-12-31 | $1.57B | $219.00M |
| 2017-12-31 | $2.25B | $220.00M |
| 2016-12-31 | $2.70B | $241.00M |
Dividend history
- Most recent payment
- 2026-02-19
- Paid in the last twelve months
- $2.15
| Payment date | Dividend per share |
|---|
| 2026-02-19 | $2.15 |
| 2025-08-08 | $1.03 |
| 2025-02-21 | $2.10 |
| 2024-08-09 | $1.00 |
| 2024-02-22 | $1.97 |
| 2023-08-10 | $0.93 |
| 2023-02-23 | $1.97 |
| 2022-08-11 | $0.93 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $2.17
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-27 | Jun/2026 | $2.50 |
| 2026-04-29 | - | - |
| 2026-02-10 | - | - |
| 2025-11-06 | - | - |
| 2025-07-29 | - | - |
| 2025-04-29 | - | - |
| 2025-02-06 | - | - |
| 2024-11-12 | - | - |
Filings and sources
- Company website
- astrazeneca.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Eli Lilly & Co (LLY) · Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · Merck & Co., Inc. (MRK) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD) · Pfizer Inc (PFE) · Bristol Myers Squibb Co (BMY)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades